Keyphrases
Levodopa
100%
Older Adults
100%
Topical Application
100%
Retinal Function
100%
Eye Drops
75%
Levodopa-carbidopa
75%
Clinically Significant
50%
Retinal Structure
50%
Ocular Disorders
50%
Multifocal Electroretinogram (mfERG)
50%
Therapeutic Solutions
25%
Dysregulated
25%
Placebo
25%
Myopia
25%
Fellow Eye
25%
Consecutive Days
25%
Dysregulation
25%
End of Treatment
25%
Dopamine
25%
Phase I Trial
25%
Visual Acuity
25%
High Dose
25%
Regional Analysis
25%
Healthy Males
25%
Pharmacokinetic Analysis
25%
Short-term Use
25%
Retinal Thickness
25%
Optical Coherence Tomography
25%
Normal Vision
25%
Dopaminergic System
25%
Dopamine System
25%
Translational Relevance
25%
Frequency Doubling Perimetry
25%
Regional Frequency
25%
Retinal Thinning
25%
Retinal Thickness Map
25%
Medicine and Dentistry
Topical Drug Administration
100%
Levodopa
100%
Low Drug Dose
75%
Carbidopa/Levodopa
75%
Eye Disease
50%
Placebo
25%
Pharmacokinetic
25%
Phase I Trials
25%
Visual Acuity
25%
Visual Field Test
25%
Optical Coherence Tomography
25%
Drug Megadose
25%
Dopaminergic System
25%
Pharmacology, Toxicology and Pharmaceutical Science
Levodopa
100%
Carbidopa Plus Levodopa
75%
Eye Disease
50%
Mole (Insectivora)
50%
Pharmacokinetic
25%
Placebo
25%
Phase I Trials
25%
Dopamine Receptor Stimulating Agent
25%
Leporidae
25%